Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2013

01-12-2013 | Brief Report

Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox

Authors: Lynnette M. Jones, Lee Stoner, Casey Brown, Chris Baldi, Blair McLaren

Published in: Breast Cancer Research and Treatment | Issue 3/2013

Login to get access

Abstract

With better detection and treatment, breast cancer is less likely to be the primary cause of death in the majority of breast cancer survivors; mortality due to cardiovascular disease (CVD) is now more common. Given the long latency periods between cancer treatment completion and potential symptomatic CVD, there is a need to detect vascular changes before symptoms appear. This short review provides an overview of non-invasive, widely available, and relatively inexpensive techniques for assessing endothelial function, central and regional arterial stiffness, central blood pressures, and intima-media thickness. These tools exhibit acceptable reliability and validity, and are relatively practical. Clinical assessment recommendations are also provided. There is sufficient evidence to encourage the use of these techniques as a component of routine serial assessments, and to help guide appropriate treatment strategies.
Literature
1.
Ministry of Health (2012) Cancer patient survival change over time update: covering the period 1994 to 2009. Ministry of Health, Wellington
2.
Gondos A, Bray F, Brewster DH et al (2008) Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer 44:1463–1475PubMedCrossRef
3.
Karim-Kos HE, de Vries E, Soerjomataram I et al (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44:1345–1389PubMedCrossRef
4.
5.
Colzani E, Liljegren A, Johansson ALV et al (2011) Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29:4014–4021PubMedCrossRef
6.
Lancellotti P, Nkomo VT, Badano LP et al (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14:721–740PubMedCrossRef
7.
Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815PubMedCrossRef
8.
Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR (2012) Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 118:2270–2276PubMedCrossRef
9.
American Cancer Society (2011) Global cancer facts & figures, 2nd edn. American Cancer Society, Atlanta
10.
Yancik R, Wesley MN, Ries LG et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885–892PubMedCrossRef
11.
Chen T, Xu T, Li Y et al (2011) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37:312–320PubMedCrossRef
12.
13.
Hedhli N, Russell KS (2011) Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev 7:221–233PubMedCrossRef
14.
Volkova M, Russell R III (2011) Anthracycline toxicity: prevalance, pathogenesis and treatment. Curr Cardiol Rev 7:214–220PubMedCrossRef
15.
Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247PubMedCrossRef
16.
Bonita R, Pradhan R (2013) Cardiovascular toxicities of cancer chemotherapy. Semin Oncol 40:156–167PubMedCrossRef
17.
Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910–3916PubMedCrossRef
18.
Lahtinen R, Kuikka J, Nousiainen T et al (1991) Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 46:301–305PubMedCrossRef
19.
Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811–7819PubMedCrossRef
20.
Suter TM, Procter M, van Veldhuisen DJ et al (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859–3865PubMedCrossRef
21.
Menna P, Paz OG, Chello M et al (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11:S21–S36PubMedCrossRef
22.
Demirci S, Nam J, Hubbs JL et al (2009) Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys 73:980–987PubMedCrossRef
23.
Johansen S, Tjessem KH, Fossa K et al (2013) Dose distribution in the heart and cardiac chambers following 4-field radiation therapy of breast cancer: a retrospective study. Breast Cancer Basic Clin Res 7:41–49CrossRef
24.
Halle M, Gabrielsen A, Paulsson-Berne G et al (2010) Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. J Am Coll Cardiol 55:1227–1236PubMedCrossRef
25.
Azim HA Jr, de Azambuja E, Colozza M et al (2011) Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 22:1939–1947PubMedCrossRef
26.
Ben Aharon I, Bar Joseph H, Tzabari M et al (2013) Doxorubicin-induced vascular toxicity—targeting potential pathways may reduce procoagulant activity. PLoS One 8:e75157PubMedCrossRef
27.
Bar-Joseph H, Ben-Aharon I, Tzabari M et al (2011) In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 6:e23492PubMedCrossRef
28.
Muzaffar K, Collins SL, Labropoulos N, Baker WH (2000) A prospective study of the effects of irradiation on the carotid artery. Laryngoscope 110:1811–1814PubMedCrossRef
29.
Stewart FA, Hoving S, Russell NS (2010) Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 174:865–869PubMedCrossRef
30.
Chaosuwannakit N, D’Agostino R, Hamilton CA et al (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28:166–172PubMedCrossRef
31.
Drafts BC, Twomley KM, D’Agostino R Jr et al (2013) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6:877–885PubMedCrossRef
32.
Kalabova H, Melichar B, Ungermann L et al (2011) Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 28:1281–1287PubMedCrossRef
33.
Mizia-Stec K, Goscinska A, Mizia M et al (2013) Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 71:681–690PubMedCrossRef
34.
O’Rourke MF, Kelly RP (1993) Wave reflection in the systemic circulation and its implications in ventricular function. J Hypertens 11:327–337PubMedCrossRef
35.
36.
Lekakis J, Abraham P, Balbarini A et al (2011) Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 18:775–789PubMedCrossRef
37.
Stoner L, Sabatier MJ (2012) Use of ultrasound for non-invasive assessment of flow-mediated dilation. Journal of Atherosclerosis and Thrombosis 19:407–412PubMedCrossRef
38.
Corretti MC, Anderson TJ, Benjamin EJ et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265PubMedCrossRef
39.
Inaba Y, Chen JA, Bergmann SR (2010) Prediction of future cardiovascular outcomes by flow-mediated vasodilation of brachial artery: a meta analysis. Int J Cardiovasc Imaging 25:705–711
40.
Pala S, Kahveci G, Akcakoyun M et al (2009) Reliability of ultrasonography in detecting flow mediated dilation. Int J Cardiovasc Imaging 25:705–711PubMedCrossRef
41.
Welsch MA, Allen JD, Geaghan JP (2002) Stability and reproducibility of brachial artery flow-mediated dilation. Med Sci Sports Exerc 34:960–965PubMedCrossRef
42.
Stoner L, Tarrant MA, Fryer S, Faulkner J (2013) How should flow-mediated dilation be normalized to its stimulus?. Clin Physiol Funct Imaging 33:75–78PubMedCrossRef
43.
Woodman RJ, Playford DA, Watts GF et al (2001) Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 91:929–937PubMed
44.
Ikonomidis I, Papadimitriou C, Vamvakou G et al (2008) Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. Growth Factors 26:117–124PubMedCrossRef
45.
Nastri CO, Martins WP, Ferriani RA et al (2008) Sonographic evaluation of endothelial function in letrozole and tamoxifen users. Maturitas 61:340–344PubMedCrossRef
46.
Stamatelopoulos KS, Lekakis JP, Poulakaki NA et al (2004) Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 147:1093–1099PubMedCrossRef
47.
Chirinos JA (2012) Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 5:243–255PubMedCrossRef
48.
Kullo IJ, Malik AR (2007) Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol 49:1413–1426PubMedCrossRef
49.
Laurent S, Cockcroft J, Van Bortel L et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605PubMedCrossRef
50.
Zoungas S, Asmar RP (2007) Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol 34:647–651PubMedCrossRef
51.
Nelson AJ, Worthley SG, Cameron JD et al (2009) Cardiovascular magnetic resonance-derived aortic distensibility: validation and observed regional differences in the elderly. J Hypertens 27:535–542PubMedCrossRef
52.
Calabia J, Torguet P, Garcia M et al (2011) Doppler ultrasound in the measurement of pulse wave velocity: agreement with the Complior method. Cardiovasc Ultrasound 9:13PubMedCrossRef
53.
Grotenhuis HB, Westenberg JJM, Steendijk P et al (2009) Validation and reproducibility of aortic pulse wave velocity as assessed with velocity-encoded MRI. J Magn Reson Imaging 30:521–526PubMedCrossRef
54.
Jatoi NA, Mahmud A, Bennett K, Feely J (2009) Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques*. J Hypertens 27:2186–2191PubMedCrossRef
55.
The Reference Values for Arterial Stiffness C (2010) Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31:2338–2350CrossRef
56.
Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55:1318–1327PubMedCrossRef
57.
Climie RED, Schultz MG, Nikolic SB et al (2012) Validity and reliability of central blood pressure estimated by upper arm oscillometric cuff pressure. Am J Hypertens 25:414–420PubMedCrossRef
58.
Weber T, O’Rourke KS, Kvas E et al (2005) Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. Eur Heart J 26:2657–2663PubMedCrossRef
59.
Vlachopoulos C, Aznaouridis K, O’Rourke MF et al (2010) Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 31:1865–1871PubMedCrossRef
60.
Weber T, O’Rourke MF, Lassnig E et al (2010) Pulse waveform characteristics predict cardiovascular events and mortality in patients undergoing coronary angiography. J Hypertens 28:797–805PubMedCrossRef
61.
Smith JC, Bennett S, Evans LM et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267PubMedCrossRef
62.
Zuo J-L, Li Y, Yan Z-J et al (2010) Validation of the central blood pressure estimation by the SphygmoCor system in Chinese. Blood Press Monit 15:268–274PubMedCrossRef
63.
Lin ACW, Lowe A, Sidhu K et al (2012) Evaluation of a novel sphygmomanometer, which estimates central blood pressure from analysis of brachial artery suprasystolic pressure waves. J Hypertens 30:1743–1750PubMedCrossRef
64.
Lowe A, Harrison W, El-Aklouk E et al (2009) Non-invasive model-based estimation of aortic pulse pressure using suprasystolic brachial pressure waveforms. J Biomech 42:2111–2115PubMedCrossRef
65.
Agabiti-Rosei E, Mancia G, O’Rourke MF et al (2007) Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 50:154–160PubMedCrossRef
66.
Avolio AP, Van Bortel LM, Boutouyrie P et al (2009) Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension 54:375–383PubMedCrossRef
67.
Sharman JE, Marwick TH, Gilroy D et al (2013) Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. Hypertension. doi:10.​1161/​HYPERTENSIONAHA.​1113.​02001
68.
Peters SA, den Ruijter HM, Palmer MK et al (2012) Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. J Intern Med 271:247–256PubMedCrossRef
69.
Bots ML, Sutton-Tyrrell K (2012) Lessons from the past and promises for the future for carotid intima-media thickness. J Am Coll Cardiol 60:1599–1604PubMedCrossRef
70.
Greenland P, Alpert JS, Beller GA et al (2010) 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 56:e50–e103PubMedCrossRef
71.
Peters SAE, Grobbee DE, Bots ML (2011) Carotid intima-media thickness: a suitable alternative for cardiovascular risk as outcome? Eur J Cardiovasc Prev Rehabil 18:167–174PubMedCrossRef
72.
Lorenz MW, Markus HS, Bots ML et al (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459–467PubMedCrossRef
73.
Howard G, Sharrett AR, Heiss G et al (1993) Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24:1297–1304PubMedCrossRef
74.
Redberg RF, Vogel RA, Criqui MH et al (2003) Task force #3—what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol 41:1886–1898PubMedCrossRef
75.
Salonen JT, Salonen R (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87:1156–1165
76.
Melichar B, Kalabova H, Krcmova L et al (2009) Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res 29:3337–3346PubMed
77.
Kobayashi K, Akishita M, Yu W et al (2004) Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 173:13–18PubMedCrossRef
78.
Koivistoinen T, Virtanen M, Hutri-Kahonen N et al (2012) Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the Cardiovascular Risk in Young Finns Study and the Health 2000 Survey. Atherosclerosis 220:387–393PubMedCrossRef
79.
Yan RT, Anderson TJ, Charbonneau F et al (2005) Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 45:1980–1986PubMedCrossRef
80.
Holewijn S, den Heijer M, Kiemeney LA et al (2014) Combining risk markers improves cardiovascular risk prediction in women. Clin Sci 126:139–146PubMedCrossRef
81.
Stoner L, Lambrick DM, Faulkner J, Young J (2013) Guidelines for the use of pulse wave analysis in adults and children. J Atheroscler Thromb 20:404–406PubMedCrossRef
82.
Carver JR, Szalda D, Ky B (2013) Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 40:229–238PubMedCrossRef
83.
Hamilton PK, Lockhart CJ, Quinn CE, McVeigh GE (2007) Arterial stiffness: clinical relevance, measurement and treatment. Clin Sci (Lond) 113:157–170CrossRef
84.
Papaioannou TG, Protogerou AD, Nasothimiou EG et al (2012) Assessment of differences between repeated pulse wave velocity measurements in terms of ‘bias’ in the extrapolated cardiovascular risk and the classification of aortic stiffness: is a single PWV measurement enough? J Hum Hypertens 26:594–602PubMedCrossRef
85.
Matsui Y, Kario K, Ishikawa J et al (2004) Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously assessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients. Hypertens Res 27:851–857PubMedCrossRef
86.
Laugesen E, Rossen NB, Hoyem P et al (2013) Reproducibility of pulse wave analysis and pulse wave velocity in patients with type 2 diabetes. Scand J Clin Lab Invest 73:428–435PubMedCrossRef
87.
Sharman JE, Marwick TH, Gilroy D et al (2013) Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. Hypertension. doi:10.​1161/​HYPERTENSIONAHA.​113.​02001
88.
Ghiadoni L, Faita F, Salvetti M et al (2012) Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens 30:1399–1405PubMedCrossRef
89.
Inaba Y, Chen JA, Bergmann SR (2010) Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 26:631–640PubMedCrossRef
90.
Stoner L, Sabatier MJ (2012) Use of ultrasound for non-invasive assessment of flow-mediated dilation. J Atheroscler Thromb 19:407–421PubMedCrossRef
Metadata
Title
Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox
Authors
Lynnette M. Jones
Lee Stoner
Casey Brown
Chris Baldi
Blair McLaren
Publication date
01-12-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2766-9

Other articles of this Issue 3/2013

Breast Cancer Research and Treatment 3/2013 Go to the issue

Review

Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002

Epidemiology

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

Events

Acknowledgement of reviewers 2013

Clinical trial

Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients

Epidemiology

Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis

Epidemiology

Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits